Predicting the Societal Value of Lecanemab in Early Alzheimer’s Disease in Japan: A Patient-Level Simulation

INTRODUCTION: Alzheimer’s disease (AD), a neurodegenerative disorder that progresses from mild cognitive impairment (MCI) to dementia, is responsible for significant burden on caregivers and healthcare systems. In this study, data from the large phase III CLARITY AD trial were used to estimate the s...

Descripción completa

Detalles Bibliográficos
Autores principales: Igarashi, Ataru, Azuma, Mie Kasai, Zhang, Quanwu, Ye, Weicheng, Sardesai, Aditya, Folse, Henri, Chavan, Ameya, Tomita, Kiyoyuki, Tahami Monfared, Amir Abbas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10310671/
https://www.ncbi.nlm.nih.gov/pubmed/37188886
http://dx.doi.org/10.1007/s40120-023-00492-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10310671/
https://www.ncbi.nlm.nih.gov/pubmed/37188886
http://dx.doi.org/10.1007/s40120-023-00492-7

Ejemplares similares